

# Santa Paula Hospital ED / Inpatient

SPH ED/IP ANTIBIOGRAM 2023 GRAM <b>NEGATIVE</b> % SUSCEPTIBLE (of Isolates tested)	# of isolates tested	Amp/Sulbactam	Cefazolin*	Cefepime	Ceftazidime	Ceftriaxone	Ciprofloxacin	Ertapenem	Gentamicin	Levofloxacin	Meropenem	Nitrofurantoin*	Pip/Tazobactam	Tobramycin	Trimethoprim/Sulfa
<i>E. coli</i>	363	59	85	90	88	87	74	100	88	68	(100)	98	95	88	67
<i>Klebsiella pneumoniae</i>	78	74	83	86	85	85	81	99	94	79	(100)	31	95	88	83
<i>Proteus mirabilis</i>	42	93	95	100	93	95	76	100	95	76	(100)	0	98	95	90
<i>Pseudomonas aeruginosa</i>	38	0	0	89	92	0	84	0	82	84	97	0	89	89	0

\*Nitrofurantoin and cefazolin: use only for the treatment of uncomplicated cystitis.

Cefazolin results predict results for oral cephalexin and cefuroxime when used to treat uncomplicated cystitis.

X: not tested

N: not recommended

( ): presumed susceptibility

13% of *E. coli* are Extended Spectrum Beta Lactamase (ESBL) Producing.

22% of *Klebsiella pneumoniae* are ESBL Producing.

SPH ED/IP ANTIBIOGRAM 2023 GRAM <b>POSITIVE</b> % SUSCEPTIBLE (of Isolates tested)	# of isolates tested	Amox/Clavulinate	Amp/Sulbactam	Ampicillin	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	Clindamycin	Erythromycin	Levofloxacin	Oxacillin	Penicillin	Tetracycline	Trimethoprim/Sulfa	Vancomycin
<i>Staphylococcus aureus</i> (MSSA)	38	N	N	0	(100)	X	X	N	83	N	N	100	0	87	87	100
<i>Staphylococcus aureus</i> (MRSA)	24	0	0	0	0	0	0	N	85	N	N	0	0	85	92	100
<i>Enterococcus faecalis</i>	44	X	X	100	0	0	0	N	0	7	N	X	X	11	0	98

X: not tested

N: not recommended

( ): presumed susceptibility

39% of *Staphylococcus aureus* are Methicillin Resistant (MRSA).

61% of *Staphylococcus aureus* are Methicillin Susceptible (MSSA).

*Streptococcus pneumoniae*: too few isolates to report.

Data from isolate totals < 30 may be statistically unreliable.

VCMC/SPH Antimicrobial Stewardship Committee 3/14/2024.